



Correction to: Validation of the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011, and proposal of a new 2020 version

Takako Saeki¹ · Mitsuhiro Kawano² · Tasuku Nagasawa³ · Yoshifumi Ubara⁴ · Yoshinori Taniguchi⁵ · Motoko Yanagita⁶ · Shinichi Nishi⁷ · Michio Nagata⁸ · Satoshi Hisano⁹ · Yutaka Yamaguchi¹⁰ · Hideki Nomura¹¹ · Takao Saito¹² · Hitoshi Nakashima¹³

Published online: 3 March 2021
© Japanese Society of Nephrology 2021

Correction to:
Clinical and Experimental Nephrology (2021) 25:99–109
<https://doi.org/10.1007/s10157-020-01993-7>

In the original publication of the article, the sensitivity% of the Plan C-1 value in Table 6 has appeared incorrectly as 90.0. The correct value should be 90.9. The corrected Table 6 is given below.

The original article can be found online at <https://doi.org/10.1007/s10157-020-01993-7>.

✉ Takako Saeki
saekit@nagaoka.jrc.or.jp

¹ Department of Internal Medicine, Nagaoka Red Cross Hospital, Senshu 2-297-1, Nagaoka, Niigata 940-2085, Japan

² Department of Rheumatology, Graduate School of Medical Science, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan

³ Division of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Hospital, 1-1 Seiryō-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan

⁴ Rheumatology Department and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan

⁵ Department of Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School Hospital, Kochi University, 185-1 Kohasu, Oko-cho, Nankoku-shi, Kochi 783-8505, Japan

⁶ Department of Nephrology, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Kyoto 606-8507, Japan

⁷ Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan

⁸ Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan

⁹ Department of Pathology, University of Occupational and Environmental Health, 1-1, Iseigaoka, Yahatanishi-ku, Kitakyushu-shi, Fukuoka 807-8555, Japan

¹⁰ Yamaguchi's Pathology Laboratory, Chiba, Japan

¹¹ Department of General Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan

¹² Sanko Clinic, Fukuoka, 4-9-3 Roppon-Matsu, Chuo-ku, Fukuoka 810-0044, Japan

¹³ Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan

Table 6 Performance of the original version and each revised version

	Sensitivity (%)	Specificity (%)	Positive likelihood ratio	Negative likelihood ratio
2011 criteria	72.7	90.0	7.27	0.30
Plan A	62.0	90.0	6.20	0.42
Plan B	94.5	76.0	3.94	0.07
Plan C-1	90.9	90.0	9.09	0.10
Plan C-2	87.3	90.0	8.73	0.14
Plan C-3	85.5	90.0	8.55	0.16
Plan C-4	80.0	90.0	8.00	0.22

Plan A: Change the pathology-related item: dense lymphoplasmacytic infiltration with (a) IgG4-positive plasma cells > 10/high power field (HPF) and/or (b) IgG4/IgG-positive plasma cells > 40% to “(a) and (b)”

Plan B: Deletion the item “storiform fibrosis” from among histologic findings in the kidney

Plan C: Addition the item “imaging or clinical findings compatible with extra-renal organ(s)” as an extra-renal organ(s) item

Plan C-1: 1) bilateral lacrimal gland swelling or 2) bilateral submandibular or parotid gland swelling, or 3) imaging findings compatible with type 1 autoimmune pancreatitis, or 4) imaging features of retroperitoneal fibrosis

Plan C-2: 1) and 2), or 3), or 4)

Plan C-3: 1) or 2), or 3)

Plan C-4: 1) and 2), or 3)

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.